Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1412-1414

  Aoki, Jun ^a   Ohashi, Kazuteru ^a   Kobayashi, Takeshi ^a   Kakihana, Kazuhiko ^a   Hirashima, Yuka ^a   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; LEUKOCYTE ANTIGEN; NILOTINIB; STEROID;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; EDEMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; JAPANESE; LETTER; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; LYMPHOCYTOSIS; MUTATION; MYALGIA; PLEURA EFFUSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; SEX CHROMOSOME; SHORT TANDEM REPEAT; SIBLING; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862746510     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.649753     Document Type: Letter

References (10)

1. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
2. Saglio G, Kim DW, Issaragrisil S, et al.; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
3. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/ NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.
4. Nagata Y, Ohashi K, Fukuda S, et al. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010;91:799-807.
5. Yoshida C, Fletcher L, Ohashi K, et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 2011 Oct 12. [Epub ahead of print]
6. Mahon FX, Réa D, Guilhot J, et al.; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
7. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719-1724.
8. Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 2009;145:5815-5897.
9. Wong SF. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia. J Oncol Pharm Pract 2009;15:17-27.
10. Yamamoto M, Kakihana K, Ohashi K, et al. Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR. Int J Hematol 2009;89:482-488.